28 November 2017Big Pharma

Teva addresses ‘internal inefficiencies’ with restructuring

Israel-headquartered Teva has announced a series of organisational and leadership changes as it seeks to address external pressures and internal inefficiencies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Asia
14 February 2019   Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.

More on this story

Biotechnology
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Asia
14 February 2019   Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.

More on this story

Biotechnology
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Asia
14 February 2019   Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.